EGFR and neoplasm: Finally, we generated a virtual patient population using published clinical data on BRAF, MEK, and EGFR antagonists, which accurately predicted population level-tumor responses to single agent treatment with the ERKi GDC-0994, and projected strategies to increase the single agent responses.